What Is Atypical Lymphoid Infiltrate?

An atypical lymphoid infiltrate is a collection of immune cells, specifically lymphocytes, found in tissue that a pathologist cannot confidently classify as either harmless or cancerous. The term is descriptive rather than a final diagnosis: it signals that the tissue sample has worrisome features but does not meet all the criteria needed to call it lymphoma. These lesions occupy a biological middle ground, and their clinical significance ranges from a drug side effect that clears up on its own to a precursor of an aggressive blood cancer. Understanding what the term means, why it appears on a pathology report, and what usually happens next can take a lot of the anxiety out of an otherwise unsettling finding.

Why Pathologists Use the Term “Atypical”

Lymphocytes are white blood cells that normally patrol your tissues looking for infections and damaged cells. When they accumulate somewhere in larger-than-expected numbers, pathologists call the collection a lymphoid infiltrate. Most of the time the pattern is clearly reactive, meaning it is an appropriate immune response to an infection, a wound, or an irritant. And most of the time a lymphoma has unmistakable features under the microscope. The trouble arises with infiltrates that fall between those two poles: they have some characteristics that raise concern for cancer but lack enough evidence to make that call definitively.

Atypical lymphoid proliferation (the broader category these lesions belong to) is recognized as a biologically indeterminate group that has some likelihood of eventually transforming into lymphoma but cannot be labeled malignant using the tools currently available.¹ The label is not a hedge born out of laziness. It reflects a genuine limitation: no single microscopic feature, no single stain, and no single molecular test can always draw a clean line between a vigorous immune reaction and an early lymphoma. As one widely cited dermatopathology review puts it, the overall balance of clinical, histopathological, immunophenotypic, and molecular features has to be weighed together before a diagnosis can be settled.²

Common Triggers

Many atypical lymphoid infiltrates have an identifiable cause, and recognizing that cause often resolves the diagnostic uncertainty. Triggers fall into a few broad categories.

Medications

Certain drugs can push the immune system into overdrive in the skin or other organs, producing dense collections of lymphocytes that closely mimic lymphoma under the microscope and sometimes even clinically. This phenomenon, sometimes called drug-induced pseudolymphoma, can resemble either T-cell or B-cell lymphomas.³ A study of 22 patients with atypical lymphoid hyperplasia linked to medications found that calcium-channel blockers, ACE inhibitors, antidepressants, antihistamines, beta-blockers, benzodiazepines, and lipid-lowering agents were among the most common culprits. Lesions resolved in the vast majority of those patients within about one to eight months of stopping the offending drug.⁴ These drug reactions can be dramatic enough to include large, abnormal-looking CD30-positive cells, a marker often associated with certain lymphomas, yet still resolve completely once the medication is withdrawn.⁵

This is why a thorough medication history is one of the first things a dermatologist or pathologist should consider when confronted with a worrisome biopsy. The same study that documented the 22 drug-associated cases specifically recommended that a diagnosis of drug-associated pseudolymphoma be excluded before anyone renders a diagnosis of cutaneous lymphoma.⁴

Infections

Bacterial infections, arthropod bites, and contact dermatitis are well-documented triggers of cutaneous pseudolymphoma, which is essentially a benign atypical lymphoid infiltrate in the skin.⁶ Herpes simplex virus can also provoke T-cell pseudolymphomas that look alarming on biopsy.⁷ In the stomach, chronic Helicobacter pylori infection is a particularly important cause. The lymphoid tissue that H. pylori provokes in the gastric lining can be extremely difficult to distinguish from low-grade MALT lymphoma. In one study, eradicating the bacteria with antibiotics led to histological regression of the infiltrate in over three-quarters of patients, confirming that most of those infiltrates were reactive rather than malignant.⁸

Autoimmune Disease

Chronic autoimmune conditions can drive persistent lymphoid infiltration that blurs the line between inflammation and early malignancy. Sjögren’s syndrome is the textbook example. The disease is defined by lymphocytic infiltration of the salivary and lacrimal glands, and roughly half of patients progress to a stage where lymphocytes damage other organs as well.⁹ The long-term risk of progressing from that chronic infiltration to an actual non-Hodgkin lymphoma is well established, and researchers have recently identified specific immune-cell subtypes in the blood of Sjögren’s patients that appear to predict which individuals are headed toward lymphoma.¹⁰

No Identifiable Cause

A significant number of cutaneous pseudolymphomas and other atypical lymphoid infiltrates are idiopathic, meaning no trigger is ever found.⁶ That does not automatically make them more dangerous, but it does make follow-up more important because there is no modifiable cause to remove.

Where These Infiltrates Show Up

The skin is probably the most common site where atypical lymphoid infiltrates are biopsied and debated. Cutaneous lymphoid infiltrates are a routine finding in dermatopathology, and the challenge of sorting them into benign or malignant categories is a daily issue for skin pathologists.² Skin infiltrates can present as red or violet bumps, plaques, or nodules that may sit around for weeks to months and look disturbingly similar to cutaneous lymphoma on first glance.

The gastrointestinal tract is another common location, especially in the stomach. As noted, H. pylori-driven gastric infiltrates can be nearly indistinguishable from early MALT lymphoma. The eye socket is a less common but clinically important site: orbital and conjunctival lymphoid infiltrates sit in an anatomic space where even a small lesion can cause noticeable symptoms like swelling, double vision, or a visible mass. In one study of orbital infiltrates, whether the lymphocytes produced a single type of antibody (monotypic) versus a mixture (polytypic) turned out to strongly predict clinical behavior, with monotypic infiltrates carrying a 50 percent risk of spreading beyond the orbit.¹¹

Atypical lymphoid infiltrates also appear in lymph nodes, the lungs, the liver, and virtually any organ where lymphocytes can accumulate. The diagnostic challenge is similar everywhere: the infiltrate looks suspicious but does not clearly cross the line into lymphoma.

How Pathologists Try to Sort It Out

Several layers of testing help a pathologist move from uncertainty toward a working diagnosis. The process usually starts with the tissue appearance under the microscope and adds progressively more specialized tools.

Immunohistochemistry and Cell Markers

Pathologists stain tissue sections with antibodies that light up specific proteins on cell surfaces. A key question for B-cell infiltrates is whether the cells show light-chain restriction, meaning they all produce either kappa or lambda antibody chains rather than a healthy mix of both. Light-chain restriction is one of the strongest indicators that a B-cell population is clonal and therefore more likely to be a lymphoma or a precursor to one.¹² An early landmark study of 40 extranodal lymphoid infiltrates found that polyclonal populations (a healthy mix of cell types) consistently correlated with benign features, while monoclonal populations consistently correlated with malignant ones.¹³

CD30 is another marker that deserves mention. Many infectious and inflammatory skin conditions can produce large numbers of CD30-positive cells, which can mimic lymphomatoid papulosis or anaplastic large cell lymphoma even though the process is entirely benign.¹⁴ Finding CD30-positive cells in a biopsy is therefore not by itself evidence of cancer; the clinical context matters enormously.

Molecular Clonality Testing

When staining results are ambiguous, pathologists often turn to molecular methods that look for clonal gene rearrangements. Every lymphocyte rearranges segments of its antigen-receptor genes during development. In a reactive process, you get a diverse chorus of different rearrangements. In a lymphoma, one malignant clone dominates, producing a detectable monoclonal band. PCR-based methods can detect clonal rearrangements of immunoglobulin heavy chain genes or T-cell receptor genes in formalin-fixed, paraffin-embedded tissue, making them practical for routine biopsy specimens.¹⁵

There is an important caveat. A monoclonal result does not always mean cancer. Drug-associated lymphoid reactions, for example, can show monoclonal T-cell receptor rearrangements on PCR without actually being lymphoma. Recognizing this pattern helps avoid misdiagnosis.¹⁶ Clonality testing is a powerful piece of the puzzle, but it still has to be interpreted alongside everything else.

Next-Generation Sequencing Is Changing the Landscape

Traditional PCR-based clonality testing has well-known sensitivity limitations, particularly for T-cell infiltrates. Next-generation sequencing (NGS) of T-cell receptor genes has emerged as a more sensitive alternative. A scoping review found that NGS-based methods detected T-cell clonality with sensitivities ranging from about 69 to 100 percent, compared to roughly 44 to 72 percent for conventional PCR, with specificity also improved.¹⁷ That kind of improvement matters most in exactly the cases where the diagnosis is uncertain.

Broader NGS panels that look for cancer-associated somatic mutations alongside gene rearrangements are also proving useful, especially in small biopsies where tissue is limited. One study found that NGS results changed the diagnostic assessment in roughly three-quarters of the cases tested, either shifting the diagnosis outright or altering the likelihood estimate.¹⁸ These tools are not yet universally available, but they are increasingly part of the workup at academic medical centers when standard methods leave the diagnosis in limbo.

How Likely Is Progression to Lymphoma

This is the question most patients really want answered when they see “atypical lymphoid infiltrate” on their pathology report. The honest answer is that it depends heavily on the site, the cause, and the cell-marker profile.

For drug-induced infiltrates, the prognosis is generally excellent. Once the offending medication is stopped, most lesions disappear within weeks. The situation in the stomach is similarly reassuring when H. pylori is the driver: antibiotic treatment led to regression in over 76 percent of cases in one series, though about 13 percent eventually revealed themselves to be true MALT lymphoma on follow-up biopsies.⁸

The orbit tells a more cautious story. Among patients with atypical lymphoid proliferation of the orbit who received no medical or radiation treatment, over a third progressed to orbital lymphoma.¹⁹ And as discussed earlier, orbital infiltrates that expressed a single antibody type carried a 50 percent risk of disseminating to other sites.¹¹ These numbers explain why orbital atypical lymphoid infiltrates tend to be managed more aggressively than, say, a solitary skin nodule with the same pathology label.

For very early, in situ-like lesions found incidentally in lymph nodes, such as follicular lymphoma in situ, current expert guidance recommends a full staging workup with imaging and bone marrow biopsy to rule out an established lymphoma hiding elsewhere. If none is found, conservative management with monitoring rather than treatment is the standard approach.²⁰

Management Approaches

Because “atypical lymphoid infiltrate” spans such a wide spectrum, there is no single treatment. Management is guided by the suspected cause, the anatomic site, and the risk profile suggested by cell markers and molecular testing.

Remove the trigger: If a medication or an infection is identified, stopping the drug or treating the infection is the first step. Many infiltrates resolve completely with this alone.
Watch and wait: For low-risk lesions, particularly those that are polyclonal and localized, periodic clinical follow-up and repeat biopsies if the lesion changes are often sufficient. This is also the recommended approach for incidentally discovered in situ lymphoid lesions when staging shows no overt lymphoma.
Excision: A solitary skin or soft-tissue nodule can sometimes be completely removed during the diagnostic biopsy itself, which may be both diagnostic and curative.
Rituximab: For B-cell-driven infiltrates in sites like the orbit where progression risk is meaningful, rituximab, a monoclonal antibody that targets the CD20 protein on B cells, is an option discussed in the literature.
Radiotherapy: External beam radiation is used primarily for orbital and other localized infiltrates that are behaving like low-grade lymphomas. It has shown favorable outcomes in orbital cases.¹⁹

The choice among these options is rarely urgent. Most atypical lymphoid infiltrates evolve slowly, giving the clinical team time to gather additional data, repeat biopsies, or consult with hematology-oncology before committing to a treatment path.

Atypical Lymphoid Infiltrates in Children

Pediatric cases deserve special mention because the same microscopic findings carry different implications in a child than in a 60-year-old adult. Gastric MALT lymphoma, for example, is overwhelmingly a disease of older adults, typically appearing after age 50 following decades of chronic H. pylori infection. When pathologists see atypical lymphoid features in a child’s stomach biopsy, the lesion almost always turns out to be reactive. One study that examined pediatric gastric biopsies found that while a small fraction of cases showed features that would meet criteria for MALT lymphoma in an adult, including monoclonal gene rearrangements and lymphoepithelial lesions, the clinical course was benign, and the authors cautioned against applying adult lymphoma criteria to children.²¹ The lesson is that context changes the meaning of the same microscopic finding, and age is one of the most important contextual clues.

Why Misdiagnosis Goes Both Ways

The conversation around atypical lymphoid infiltrates tends to focus on the fear of missing a lymphoma. That is understandable, but the opposite error, calling something lymphoma when it is actually a benign reaction, carries real consequences too. A false lymphoma diagnosis can mean unnecessary chemotherapy, radiation, or years of anxiety-laden surveillance. Drug-induced pseudolymphomas are a particular trap: the dense, atypical-looking infiltrates they produce can fool even experienced pathologists, and the monoclonal gene rearrangements sometimes found in these lesions can reinforce a mistaken cancer diagnosis if the clinical picture is not considered.¹⁶

The safest approach, and the one most pathologists advocate, is to integrate every available piece of information: the patient’s age, medication list, infection history, autoimmune status, the site of the biopsy, the microscopic pattern, the immunohistochemical stains, and the molecular results. No single data point overrules the others. That integrative philosophy is why the term “atypical lymphoid infiltrate” exists in the first place. It is an honest acknowledgment that medicine sometimes has to sit with uncertainty until enough evidence accumulates to point clearly in one direction.

Artificial Intelligence in Lymphoid Pathology

The digitization of pathology slides has opened the door to AI-based image analysis, and lymphoid infiltrates are a natural target given how subjective their interpretation can be. Research in related fields, including other skin cancers and systemic lymphomas, has shown promising results using AI for tasks like disease classification, cancer detection, and outcome prediction. Cutaneous lymphomas themselves remain minimally explored so far, but the building blocks are in place and the field is expected to grow as more centers adopt digital pathology workflows.²² Whether AI will eventually help pathologists draw a cleaner line between benign and malignant lymphoid infiltrates remains to be seen, but the combination of whole-slide imaging, molecular data, and machine learning is the direction the field is moving.

1
PubMed. Atypical lymphoid proliferations: the pathologist’s viewpoint
2
PubMed Central. Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?
3
Clinical Medical Reviews and Case Reports. Lymphoma or Pseudolymphoma, that is the Question
4
PubMed. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis
5
PubMed. Linear Folliculotropic CD30-Positive Lymphomatoid Drug Reaction
6
PubMed. Treatment of Cutaneous Pseudolymphoma: A Systematic Review
7
PubMed. T-cell pseudolymphoma in recurrent herpes simplex virus infection
8
PubMed. Atypical lymphoid infiltrations of the gastric mucosa–their interpretation and management by eradication of Helicobacter pylori
9
PubMed. Lymphoproliferative disorders in Sjögren’s syndrome
10
PubMed. Deep Immunophenotyping and Clustering Identifies Biomarkers Predictive of Lymphoma in Primary Sjögren Disease
11
Blood. Immunohistologic features predict clinical behavior of orbital and conjunctival lymphoid infiltrates
12
PubMed Central. Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates
13
Cancer. The immunologic characterization of 40 extranodal lymphoid infiltrates
14
PubMed. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin
15
American Journal of Clinical Pathology. Assessment of Clonality in Cutaneous Lymphoid Infiltrates by Polymerase Chain Reaction Analysis of Immunoglobulin Heavy Chain Gene Rearrangement
16
PubMed. Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR/DGGE
17
PubMed. Assessing T-cell receptor clonality by next-generation sequencing in atypical cutaneous lymphoid infiltrates and cutaneous T-cell lymphoma: A scoping review
18
American Journal of Clinical Pathology. Diagnostic Impact of Next-Generation Sequencing Panels for Lymphoproliferative Neoplasms on Small-Volume Biopsies
19
PubMed Central. Atypical lymphoid proliferation of the orbit
20
Haematologica. Early lymphoid lesions: conceptual, diagnostic and clinical challenges
21
The American Journal of Surgical Pathology. Atypical Lymphoid Proliferations and Clonality in Helicobacter -associated Inflammatory Infiltrates in Children
22
PubMed. Artificial intelligence in digital pathology of cutaneous lymphomas: A review of the current state and future perspectives